Cantor Fitzgerald Sticks to Its Buy Rating for Karyopharm Therapeutics

By Austin Angelo

In a report released today, Mara Goldstein from Cantor Fitzgerald reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $18. The company’s shares closed yesterday at $9.96.

Goldstein observed:

“Updated data from the SADAL study of selinexor in resistant and refractory diffuse B-cell lymphoma (DLBCL) shows an increasing ORR from the prior.”

According to, Goldstein is ranked 0 out of 5 stars with an average return of -3.8% and a 42.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Cascadian Therapeutics.

Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.17.

The company has a one year high of $14.63 and a one year low of $6.27. Currently, Karyopharm Therapeutics has an average volume of 290.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.,0844XQ-E